Effect of Trikafta on bone density, body composition and exercise capacity in CF: A pilot study-Reference-Cited by-同舟云学术

Effect of Trikafta on bone density, body composition and exercise capacity in CF: A pilot study

Published:2022-11-22 Issue:2 Volume:58 Page:577-584
ISSN:8755-6863
Container-title:Pediatric Pulmonology
language:en
Short-container-title:Pediatric Pulmonology

Author:

Gur Michal¹²^ORCID,Bar–Yoseph Ronen¹²^ORCID,Hanna Moneera¹,Abboud Dana¹,Keidar Zohar²³,Palchan Tala³,Toukan Yazeed¹²,Masarweh Kamal¹²,Alisha Irit¹,Zuckerman‐Levin Nehama²⁴,Bentur Lea¹²^ORCID

Affiliation:

1. Pediatric Pulmonary Institute and CF Center, Rappaport Children's Hospital Rambam Health Care Campus Haifa Israel

2. Rappaport Faculty of Medicine Technion–Israel Institute of Technology Haifa Israel

3. Nuclear Medicine Institute Rambam Health Care Campus Haifa Israel

4. Pediatric Diabetes Unit, Rappaport Children's Hospital Rambam Health Care Campus Haifa Israel

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ppul.26243

Reference42 articles.

1. VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

2. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors

3. FDA.FDA approves new breakthrough therapy for cystic fibrosis. Accessed May 2 2021.https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis

4. Vertex Pharmaceuticals.Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations. Accessed May 2 2021.https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-fda-approvals-trikaftar

5. Effect of CFTR Modulators on Anthropometric Parameters in Individuals with Cystic Fibrosis: An Evidence Analysis Center Systematic Review

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nutritional status in the era of highly effective CFTR modulators;Pediatric Pulmonology;2024-08-06

2. Elexacaftor–tezacaftor–ivacaftor use after solid organ transplant;Current Opinion in Pulmonary Medicine;2024-08-01

3. Impact of CFTR modulator therapy on body composition as assessed by thoracic computed tomography: A follow-up study;Nutrition;2024-07

4. Giving adolescents with cystic fibrosis a voice: Predicting cystic fibrosis nutritional adherence from their decision-making involvement;Journal of Pediatric Psychology;2024-05-16

5. Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis;Scientific Reports;2024-04-24